利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

143 条记录 (耗时 0.048 秒)

    ANTIBODIES THAT BIND TO CCR6 AND THEIR USES
    81.
    发明申请
    ANTIBODIES THAT BIND TO CCR6 AND THEIR USES 审中-公开

    公开(公告)号：US20180086836A1

    公开(公告)日：2018-03-29

    申请号：US15519413

    申请日：2015-10-19

    申请人： GLENMARK PHARMACEUTICALS S.A.

    发明人： Rami LISSILAA ,  Adrian WALMSLEY ,  Stanislas BLEIN ,  Romain OLLIER ,  Samuel HOU ,  Jeremy LOYAU

    IPC分类号： C07K16/28 ,  C07K14/715 ,  A61K47/68

    摘要： The present invention relates to antibodies or fragments thereof that bind to CCR6. More specifically, the present invention relates to an antibody or fragment thereof that binds to CCR6 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 31, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 32, SEQ ID NO: 190, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 254 or SEQ ID NO: 255 and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 33; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 34, SEQ ID NO: 191, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO: 246 or SEQ ID NO: 256, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 35, SEQ ID NO: 247, SEQ ID NO: 248 or SEQ ID NO:257 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 36 or SEQ ID NO: 192 or SEQ ID NO: 193.

    Thienopyrimidinedione derivatives as TRPA1 modulators
    88.
    发明授权
    Thienopyrimidinedione derivatives as TRPA1 modulators 有权
    噻吩并嘧啶二酮衍生物作为TRPA1调节剂

    公开(公告)号：US08987278B2

    公开(公告)日：2015-03-24

    申请号：US13925975

    申请日：2013-06-25

    申请人： Glenmark Pharmaceuticals S.A.

    发明人： Sukeerthi Kumar ,  Abraham Thomas ,  Nayan Taterao Waghmare ,  Sanjay Margal ,  Neelima Khairatkar-Joshi ,  Indranil Mukhopadhyay

    IPC分类号： A61K31/519 ,  C07D495/04

    CPC分类号： A61K31/519 ,  A61K45/06 ,  C07D495/04

    摘要： The present invention is related to novel thienopyrimidinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.

    摘要翻译： 本发明涉及新型噻吩并嘧啶二酮衍生物作为TRPA（瞬时受体电位亚族A）调节剂。 特别地，本文所述的化合物可用于治疗或预防由TRPA1（瞬时受体电位亚科A，成员1）调节的疾病，病症和/或病症。 本文还提供了制备本文所述化合物的方法，其合成中使用的中间体，其药物组合物，以及用于治疗或预防由TRPA1调节的疾病，病症和/或障碍的方法。

    HUMANIZED ANTIBODIES THAT BIND TO CD19 AND THEIR USES
    89.
    发明申请
    HUMANIZED ANTIBODIES THAT BIND TO CD19 AND THEIR USES 审中-公开
    与CD19绑定的人体抗体及其用途

    公开(公告)号：US20140286934A1

    公开(公告)日：2014-09-25

    申请号：US14168927

    申请日：2014-01-30

    申请人： GLENMARK PHARMACEUTICALS S.A.

    发明人： Stanislas BLEIN ,  Darko Skegro ,  Christophe Debonneville ,  Martin Bertschinger

    IPC分类号： C07K16/30

    CPC分类号： C07K16/3061 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/92

    摘要： The present invention relates to humanized antibodies or fragments thereof that bind to human CD19. More specifically, the present invention relates to a humanized antibody or fragment thereof that binds to human CD19 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 27, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 29; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 31 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 32.

    摘要翻译： 本发明涉及与人CD19结合的人源化抗体或其片段。 更具体地，本发明涉及与人CD19结合的人源化抗体或其片段，其包含包含SEQ ID NO：27的氨基酸序列的重链CDR1和/或包含SEQ ID NO：27的氨基酸序列的重链CDR2 SEQ ID NO：28，和/或包含SEQ ID NO：29的氨基酸序列的重链CDR3; 和/或包含包含SEQ ID NO：30的氨基酸序列的轻链CDR1和/或包含SEQ ID NO：31的氨基酸序列的轻链CDR2和/或包含氨基酸序列的轻链CDR3 的SEQ ID NO：32。